Nov 29, 2022 / 05:10PM GMT
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity Analyst
All right. Welcome, everyone. This is Joshua Schimmer from the Evercore ISI biotech team. (inaudible) President and Chief Executive Officer of Exelixis, we have Mike Morrissey. Good to see you. Welcome back to our health care conference. I'm thinking cabo is still is the primary value driver for Exelixis in the near term. So maybe we can talk about some of the trials that could drive that near-term inflection. What might be left after cabo for 092 and then hopefully have some time to talk about the evolving pipeline.
Questions and Answers:
Joshua Elliott Schimmer - Evercore ISI Institutional Equities, Research Division - Senior MD & Equity AnalystSo as we think about the major growth drivers for cabo, both within renal and then also additional indications, what should we be looking for? And like what are your highest hopes?
Michael M. Morrissey - Exelixis, Inc. - CEO, President & Director